Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Per Share data	3 Months Ended		9 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Condensed Consolidated Statements of Operations [Abstract]
Net Sales	$ 40,052	$ 33,857	$ 118,374	$ 107,461
COST OF SALES	14,626	12,121	43,046	40,073
GROSS PROFIT	25,426	21,736	75,328	67,388
OPERATING EXPENSES
Research and development	2,710	2,128	7,383	6,521
Selling and marketing	6,143	4,287	17,847	13,495
General and administrative	6,442	4,872	18,675	14,042
European and global sales & marketing leadership reorganization			1,240
Bioline Group transaction costs		673		673
Total operating expenses	15,295	11,960	45,145	34,731
OPERATING INCOME	10,131	9,776	30,183	32,657
OTHER INCOME (EXPENSE)
Interest income	26	29	70	90
Other, net	36	(9)	357	(17)
Total other income (expense)	62	20	427	73
EARNINGS BEFORE INCOME TAXES	10,193	9,796	30,610	32,730
INCOME TAX PROVISION	3,357	3,372	10,489	11,405
NET EARNINGS	$ 6,836	$ 6,424	$ 20,121	$ 21,325
BASIC EARNINGS PER COMMON SHARE	$ 0.17	$ 0.16	$ 0.49	$ 0.53
DILUTED EARNINGS PER COMMON SHARE	$ 0.17	$ 0.16	$ 0.49	$ 0.52
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	40,737	40,535	40,680	40,510
EFFECT OF DILUTIVE STOCK OPTIONS	657	616	673	656
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	41,394	41,151	41,353	41,166
ANTI-DILUTIVE SECURITIES:
Common share options	160	234	177	207
DIVIDENDS DECLARED PER COMMON SHARE	$ 0.19	$ 0.19	$ 0.57	$ 0.55